keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/27891715/baseline-hepatitis-b-core-antibody-predicts-treatment-response-in-chronic-hepatitis-b-patients-receiving-long-term-entecavir
#1
J-H Xu, L-W Song, N Li, S Wang, Z Zeng, C-W Si, J Li, Q Mao, D-Z Zhang, H Tang, J-F Sheng, X-Y Chen, Q Ning, G-F Shi, Q Xie, Q Yuan, Y-Y Yu, N-S Xia
Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) in patients with chronic hepatitis B receiving first-line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks...
November 28, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27888553/left-lobe-auxiliary-liver-transplantation-for-end-stage-hepatitis-b-liver-cirrhosis
#2
S Wang, X Chen, Z Chen, L Wei, S Dong, H Guo, J Jiang, W Teng, Z Huang, W Zhang
Auxiliary liver transplantation (ALT) for Hepatitis B virus (HBV) related liver cirrhosis previously showed poor results, because the native liver was a significant source of HBV recurrence and the graft could be rapidly destroyed by HBV infection in an immunosuppressive condition. Four patients suffering from HBV-related liver cirrhosis were unable to undergo orthotopic liver transplantation because the only available grafts of left lobe were too small. Under entecavir based anti-HBV treatment, they underwent ALT in which the recipient left liver was removed and the small left lobe graft was implanted in the corresponding space...
November 26, 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/27866195/comparison-of-telbivudine-and-entecavir-therapy-on-nephritic-function-and-drug-resistance-in-patients-with-hepatitis-b-virus-related-compensated-cirrhosis
#3
Huajiang Shen, Feng Ding, Zhiwei Wang, Fang Sun, Yafeng Yu, Jiankang Zhou, Wenfang Xu, Jianchao Ni, Jiangang Wang, Yida Yang
BACKGROUND: To compare the impact of telbivudine (LDT) and entecavir (ETV) administration on nephritic function. METHOD: One hundred thirty patients diagnosed with hepatitis B virus (HBV)-related compensated cirrhosis were randomly divided into LDT (600 mg/d) or ETV (0.5 mg/d) groups. RESULTS: The drug resistance rate was higher following LDT treatment compared to ETV treatment (16.9% vs. 1.5%, P=0.0006). The mean creatinine level decreased compared to baseline in the LDT group (0...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27862721/efficacy-and-safety-of-tenofovir-disoproxil-fumarate-rescue-therapy-for-chronic-hepatitis-b-patients-who-failed-other-nucleos-t-ide-analogues
#4
Hiromitsu Kumada, Kazuhiko Koike, Kazuaki Suyama, Hiroshi Ito, Hiroshi Itoh, Wataru Sugiura
OBJECTIVE: Acquisition of nucleos(t)ide analogue (NA) inhibitors resistance is critical in successful chronic hepatitis B treatment. As the pattern of tenofovir disoproxil fumarate (TDF) resistance mutations differs from that of other antiviral drugs, we sought to clarify the salvaging potential of TDF in HBV patients who are poor responders or resistant to other NAs. MATERIALS AND METHOD: A prospective, multi-center, one-arm, open-label study was conducted from December 2011 to October 2014...
November 15, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27858892/circulating-kidney-injury-molecule-1-is-a-novel-diagnostic-biomarker-for-renal-dysfunction-during-long-term-adefovir-therapy-in-chronic-hepatitis-b
#5
Ziyue Li, Chuan Shen, Yadong Wang, Wei Wang, Qian Zhao, Zhenzhong Liu, Yang Wang, Caiyan Zhao
The aim of this study was to evaluate serum kidney injury molecule-1 (KIM-1) as a new diagnostic marker of renal dysfunction in chronic hepatitis B (CHB) patients receiving long-term adefovir dipivoxil (ADV) treatment.We retrospectively enrolled 85 patients treated with ADV and 85 patients treated with entecavir (ETV) monotherapy, for at least 6 months. The 2 groups were matched for baseline age (± 5 years), sex, and estimated glomerular filtration rate (eGFR). Serum creatinine, cystatin C, and KIM-1 concentrations were measured, and eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin C equation, at baseline and last follow-up...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27847098/lamivudine-switch-therapy-in-chronic-hepatitis-b-patients-achieving-undetectable-hepatitis-b-virus-dna-after-3-years-of-entecavir-therapy-a-prospective-open-label-multicenter-study
#6
Ming-Lun Yeh, Ching-I Huang, Ming-Yen Hsieh, Chung-Feng Huang, Meng-Hsuan Hsieh, Jee-Fu Huang, Chia-Yen Dai, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang
The subsequent maintenance therapy in chronic hepatitis B (CHB) patients after long-term viral replication suppression is still uncertain. We aim to evaluate the efficacy of lamivudine (LAM) maintenance therapy in CHB patients achieving undetectable hepatitis B virus (HBV) DNA after 3 years of entecavir (ETV) therapy. Consecutive CHB patients who received at least 3 years of ETV and achieved HBV DNA negativity were allocated either LAM switch therapy or stopped ETV therapy in a prospective, open-label study...
November 2016: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/27845395/slow-reduction-of-ip-10-levels-predicts-hbeag-seroconversion-in-chronic-hepatitis-b-patients-with-5-years-of-entecavir-treatment
#7
Renyong Guo, Hejun Mao, Xiao Hu, Nengneng Zheng, Dong Yan, Jianqin He, Jiezuan Yang
The aim of this study was to determine the correlation between dynamic changes in serum cytokine/chemokine expression levels in response to entecavir (ETV) treatment and HBV e antigen (HBeAg) seroconversion in patients with chronic hepatitis B (CHB). Four cytokines (interleukin [IL]-4, IL-6, IL-8, and interferon-γ) and five chemokines (macro-phage inflammatory protein [MIP]-1α, MIP-1β, platelet derived growth factor-BB, and interferon-inducible protein 10 [IP-10]) before ETV therapy and at 3, 6, 12, 24, 36 and 60 months during therapy in 105 CHB patients were analyzed...
November 15, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27822262/a-cost-utility-and-cost-effectiveness-analysis-of-different-oral-antiviral-medications-in-patients-with-hbeag-negative-chronic-hepatitis-b-in-iran-an-economic-microsimulation-decision-model
#8
Khosro Keshavarz, Abbas Kebriaeezadeh, Seyed Moayed Alavian, Ali Akbari Sari, Mohsen Rezaei Hemami, Farhad Lotfi, Amir Hashemi Meshkini, Mehdi Javanbakht, Maryam Keshvari, Shekoufeh Nikfar
BACKGROUND: Although hepatitis B infection is the major cause of chronic liver disease in Iran, no studies have employed economic evaluations of the medications used to treat Iranian patients with chronic hepatitis B (CHB). Therefore, the cost-effectiveness of the different treatment options for this disease in Iran is unknown. OBJECTIVES: The aim of this study was to compare the cost utility and cost-effectiveness of medication strategies tailored to local conditions in patients with HB e antigen (HBeAg)-negative CHB infection in Iran...
September 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/27809454/long-term-real-world-entecavir-therapy-in-treatment-na%C3%A3-ve-hepatitis-b-patients-base-line-hepatitis-b-virus-dna-and-hepatitis-b-surface-antigen-levels-predict-virologic-response
#9
Ju-Yeon Cho, Won Sohn, Dong-Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Joon Hyeok Lee
Background/Aims: Entecavir is a potent nucleoside analogue with high efficacy and barrier for resistance. We aimed to investigate the long-term efficacy and viral resistance rate of entecavir and explore the factors associated with virologic response, including quantitative hepatitis B surface antigen (qHBsAg) levels. Methods: One thousand and nine treatment-naïve chronic hepatitis B (CHB) patients were evaluated for cumulative rates of virologic response, biochemical response, and entecavir mutations...
November 4, 2016: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/27801778/antiviral-screening-of-multiple-compounds-against-ebola-virus
#10
Stuart D Dowall, Kevin Bewley, Robert J Watson, Seshadri S Vasan, Chandradhish Ghosh, Mohini M Konai, Gro Gausdal, James B Lorens, Jason Long, Wendy Barclay, Isabel Garcia-Dorival, Julian Hiscox, Andrew Bosworth, Irene Taylor, Linda Easterbrook, James Pitman, Sian Summers, Jenny Chan-Pensley, Simon Funnell, Julia Vipond, Sue Charlton, Jayanta Haldar, Roger Hewson, Miles W Carroll
In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been renewed efforts to search for effective antiviral countermeasures. A range of compounds currently available with broad antimicrobial activity have been tested for activity against EBOV. Using live EBOV, eighteen candidate compounds were screened for antiviral activity in vitro. The compounds were selected on a rational basis because their mechanisms of action suggested that they had the potential to disrupt EBOV entry, replication or exit from cells or because they had displayed some antiviral activity against EBOV in previous tests...
October 27, 2016: Viruses
https://www.readbyqxmd.com/read/27800206/immune-complex-mediated-glomerulonephritis-with-acute-thrombotic-microangiopathy-following-newly-detected-hepatitis-b-virus-infection-in-a-kidney-transplant-recipient
#11
Tracey Salter, Hannah Burton, Sam Douthwaite, William Newsholme, Catherine Horsfield, Rachel Hilton
Hepatitis B virus (HBV) presents a risk to patients and staff in renal units. To minimise viral transmission, there are international and UK guidelines recommending HBV immunisation for patients commencing renal replacement therapy (RRT) and HBV surveillance in kidney transplant recipients. We report the case of a 56-year-old male who was immunised against HBV before starting haemodialysis. He received a deceased donor kidney transplant three years later, at which time there was no evidence of HBV infection...
2016: Case Reports in Transplantation
https://www.readbyqxmd.com/read/27792585/comparison-of-detection-rate-and-mutational-pattern-of-drug-resistant-mutations-between-a-large-cohort-of-genotype-b-and-genotype-c-hepatitis-b-virus-infected-patients-in-north-china
#12
Xiaodong Li, Yan Liu, Shaojie Xin, Dong Ji, Shaoli You, Jinhua Hu, Jun Zhao, Jingjing Wu, Hao Liao, Xin-Xin Zhang, Dongping Xu
The study aimed to investigate the association of prevalent genotypes in China (HBV/C and HBV/B) with HBV drug-resistant mutations. A total of 13,847 nucleos(t)ide analogue (NA)-treated patients with chronic HBV infection from North China were enrolled. HBV genotypes and resistant mutations were determined by direct sequencing and confirmed by clonal sequencing if necessary. HBV/B, HBV/C, and HBV/D occupied 14.3%, 84.9%, and 0.8% across the study population, respectively. NA usage had no significant difference between HBV/B- and HBV/C-infected patients...
October 28, 2016: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/27789659/induction-of-ifn-%C3%AE-3-as-an-additional-effect-of-nucleotide-not-nucleoside-analogues-a-new-potential-target-for-hbv-infection
#13
Kazumoto Murata, Mai Asano, Akihiro Matsumoto, Masaya Sugiyama, Nao Nishida, Eiji Tanaka, Taisuke Inoue, Minoru Sakamoto, Nobuyuki Enomoto, Takayoshi Shirasaki, Masao Honda, Shuichi Kaneko, Hiroyuki Gatanaga, Shinichi Oka, Yuki I Kawamura, Taeko Dohi, Yasutaka Shuno, Hideaki Yano, Masashi Mizokami
OBJECTIVE: The clinical significance of polymorphisms in the interleukin-28B gene encoding interferon (IFN)-λ3, which has antiviral effects, is known in chronic HCV but not in HBV infection. Thus, we measured IFN-λ3 levels in patients with HBV and investigated its clinical significance and association with nucleos(t)ide (NUC) analogue administration. DESIGN: Serum IFN-λ3 level was measured in 254 patients with HBV with varying clinical conditions using our own high sensitivity method...
October 27, 2016: Gut
https://www.readbyqxmd.com/read/27788718/-changes-in-serum-%C3%AE-2-microglobulin-retinol-binding-protein-and-cystatin-c-and-their-value-in-identifying-early-renal-dysfunction-in-patients-with-chronic-hepatitis-b-undergoing-tenofovir-or-entecavir-monotherapy-a-comparative-analysis
#14
J He, H B Ning, Y L Zeng, W Li, K Li, J Shang
Objective: To investigate the dynamic changes in serum β2-microglobulin, retinol-binding protein, and cystatin C in chronic hepatitis B(CHB)patients treated with tenofovir or entecavir alone as the anti-HBV therapy, as well as their value in identifying early renal dysfunction. Methods: A total of 61 previously untreated CHB patients who were diagnosed and treated in the Department of Infectious Diseases in Henan Provincial People's Hospital from June 2013 to August 2015 were enrolled and divided into tenofovir group and entecavir group...
September 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/27784842/comparative-effectiveness-of-lamivudine-versus-entecavir-in-patients-with-hepatocellular-carcinoma-watch-out-for-confounders
#15
EDITORIAL
Hwi Young Kim
No abstract text is available yet for this article.
November 15, 2016: Gut and Liver
https://www.readbyqxmd.com/read/27777855/telbivudine-for-the-treatment-of-chronic-hepatitis-b-in-hbeag-positive-patients-in-china-a-health-economic-analysis
#16
S Banerjee, P Gunda, R F Drake, K Hamed
BACKGROUND: Nucleos(t)ide analogs (NUCs) are the standard of care for chronic hepatitis B (CHB). The present analysis aimed to determine the cost effectiveness of NUCs in Chinese healthcare settings. METHODS: A Markov model was used to simulate two therapeutic strategies for a hypothetical patient cohort diagnosed with hepatitis B e antigen-positive CHB, unwilling or unable to receive interferon therapy, and about to start treatment with any NUC. The first strategy included NUC monotherapy without sequencing (telbivudine [LDT], entecavir [ETV], tenofovir [TDF], lamivudine [LAM], adefovir dipivoxil [ADV], and combination therapies of either LDT and ADV or LDT and TDF, followed by best supportive care [BSC])...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27766731/tenofovir-versus-tenofovir-plus-entecavir-for-chronic-hepatitis-b-with-lamivudine-resistance-and-entecavir-resistance
#17
S Lee, S H Ahn, K S Jung, D Y Kim, B K Kim, S U Kim, O Baatarkhuu, H J Ku, K Han, J Y Park
We compared the viral suppressive efficacy of tenofovir disoproxil fumarate (TDF) mono-rescue therapy (TDF group) and TDF plus entecavir (ETV) combination-rescue therapy (TDF + ETV group) in chronic hepatitis B (CHB) patients with lamivudine resistance and entecavir resistance. One hundred and thirty-three CHB patients with lamivudine and entecavir resistance were investigated. Ninety-six patients were treated with TDF and 37 with TDF + ETV for at least 6 months. We compared the virologic response rate (HBV DNA level <20 IU/mL) between the two groups and identified the predictive factors of treatment outcome...
October 20, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27761438/treatment-for-hepatitis-b-in-patients-with-drug-resistance
#18
Frank Tacke, Daniela C Kroy
Persistent hepatitis B virus (HBV) infections affect about 240 million patients worldwide that are at risk of developing liver cirrhosis or hepatocellular carcinoma. HBV is a small, partially double stranded DNA virus with four overlapping genes and a unique life cycle, which involves the generation of an RNA template for replication via reverse transcription. Mutations occur frequently during chronic infection, and particular selection pressures select distinct mutants. Nucleoside and nucleotide analogues like lamivudine (LMV), entecavir (ETV), telbivudine (LdT), adefovir dipivoxil (ADV) and tenofovir (TDF) are used to achieve long-term suppression of viral replication...
September 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27753647/value-of-cystatin-c-based-e-gfr-measurements-to-predict-long-term-tenofovir-nephrotoxicity-in-patients-with-hepatitis-b
#19
Ali Riza Koksal, Huseyin Alkim, Salih Boga, Mehmet Sinan Iyisoy, Ilker Sen, Sebnem Tekin Neijmann, Canan Alkim
BACKGROUND: Cystatin C is a genuine marker for detecting minor reductions in estimated glomerular filtration rate (e-GFR). STUDY QUESTION: We aimed to investigate the efficiency of cystatin C levels in predicting nephrotoxicity due to antiviral therapy in patients with chronic hepatitis B virus infection. STUDY DESIGN: Seventy-six naive hepatitis B virus patients and 44 controls were enrolled in this prospective cohort study. MEASURES AND OUTCOMES: Serum cystatin C, phosphate and creatinine levels, and urinary albumin/creatinine ratios of all patients were measured at baseline, 3rd, 12th, and 24th months...
October 4, 2016: American Journal of Therapeutics
https://www.readbyqxmd.com/read/27749778/lamivudine-improves-short-term-outcome-in-hepatitis-b-virus-related-acute-on-chronic-liver-failure-patients-with-a-high-model-for-end-stage-liver-disease-score
#20
Xiaoshu Li, Fangyuan Gao, Huimin Liu, Henghui Zhang, Yao Liu, Xieqiong Ye, Mingfan Geng, Le Sun, Rui Wang, Yuxin Li, Yuyong Jiang, Xiaojing Wang, Guiqin Zhou, Zhiyun Yang, Ang Li, Hui Zeng, Xianbo Wang
AIM: Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) has significant morbidity and mortality. There is no standard approach for the management of HBV-related ACLF with nucleos(t)ide analogs. Our objective was to compare the short-term mortality between entecavir (ETV) and lamivudine (LAM) in patients with HBV-related ACLF. METHODS: We recruited 311 inpatients with HBV-related ACLF from December 2002 to January 2015. The patients were treated with ETV (n=143) or LAM (n=168)...
January 2017: European Journal of Gastroenterology & Hepatology
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"